Indoleamine 2,3-dioxygenase (IDO) is involved in promoting the development of anterior chamber-associated immune deviation

Immunology Letters

Volumn 107, Issue 2, 2006, Pages 140-147

  Chen, Xuan ^a,b   Liu, Lan ^a,b   Yang, Peizeng ^a,b   Wu, Changyou ^b   Jin, Haoli ^a   Xing, Lin ^a,b   Li, Bing ^a,b   Zhou, Hongyan ^a,b   Huang, Xiangkun ^a,b   Zhu, Lianxiang ^a,b  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Anterior chamber associated immune deviation; Indoleamine 2,3 dioxygenase; Tryptophan

Indexed keywords

INDOLEAMINE 2,3 DIOXYGENASE; MESSENGER RNA; OVALBUMIN; TRYPTOPHAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTERIOR CHAMBER ASSOCIATED IMMUNE DEVIATION; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; ENZYME INHIBITION; EYE DISEASE; FLUORESCENCE ANALYSIS; IMMUNE DEFICIENCY; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL TOLERANCE; INTERFERON PRODUCTION; LYMPH NODE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REAL TIME POLYMERASE CHAIN REACTION; SPLEEN CELL; UPREGULATION; WESTERN BLOTTING;

ANIMALS; ANTERIOR CHAMBER; BLOTTING, WESTERN; HYPERSENSITIVITY, DELAYED; IMMUNE TOLERANCE; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERFERON TYPE II; INTERLEUKIN-4; MICE; MICE, INBRED BALB C; OVALBUMIN; POLYMERASE CHAIN REACTION; SPLEEN; TRYPTOPHAN; UP-REGULATION;

EID: 33751193093     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2006.08.006     Document Type: Article

References (40)

1. Niederkorn J.Y. Immune privilege and immune regulation in the eye. Adv Immunol 48 (1990) 191-226
2. Streilein J.W. Molecular basis of ACAID. Ocul Immunol Inflamm 5 (1997) 217-218
3. Streilein J.W., Ksander B.R., and Taylor A.W. Immune deviation in relation to ocular immune privilege. J Immunol 158 (1997) 3557-3560
4. Streilein J.W., and Niederkorn J.Y. Induction of anterior chamber-associated immune deviation requires an intact, functional spleen. J Exp Med 153 (1981) 1058-1067
5. Wilbanks G.A., and Streilein J.W. Distinctive humoral immune responses following anterior chamber and intravenous administration of soluble antigen. Evidence for active suppression of IgG2-secreting B lymphocytes. Immunology 71 (1990) 566-572
6. Kosiewicz M.M., Alard P., and Streilein J.W. Alteration in cytokine production following intraocular injection of soluble protein antigen: impairment in IFN-γ and induction of TGF-β and IL-4 production. J Immunol 161 (1998) 5382-5390
7. Ferguson T.A., and Griffith T.S. A vision of cell death: insights into immune privilege. Immunol Rev 156 (1997) 167-184
8. Stein-Streilein J., and Streilein J.W. Anterior chamber associated immune deviation (ACAID): regulation, biological relevance, and implication for therapy. Inter Rev Immunol 21 (2002) 123-125
9. Koevary S.B. Ocular immune privilege: a review. Clin Eye Vision Care 12 (2000) 97-106
10. Streilein J.W., and Niederkorn J.Y. Characterization of the suppressor cells responsible for anterior chamber-associated immune deviation (ACAID) induced in BALB/c mice by P815 cells. J Immunol 134 (1985) 1381-1387
11. Wilbanks G.A., and Streilein J.W. Characterization of the suppressor cells in anterior chamber-associated immune deviation (ACAID) induced by soluble antigen. Evidence of two functionally and phenotypically distinct T-suppressor cells populations. Immunology 71 (1990) 383-389
12. Pfefferkorn E.R. Interferon-γ blocks the growth of toxoplasma gondii in human fibroblasts by inducing the host cells to degrade tryptophan. Proc Natl Acad Sci USA 81 (1984) 908-912
13. Carlin J.M., Borden E.C., Sondel P.M., and Byrne G.I. Interferon-induced indoleamine 2,3-dioxygenase activity in human mononuclear phagocytes. J Leukoc Biol 45 (1989) 29-34
14. Adams O., Besken K., Oberdorfer C., Mackenzie C.R., Russing D., and Daubener W. Role of indoleamine-2,3-dioxygenase in α/β and γ-interferon-mediated antiviral effects against herpes simplex virus infections. J Virol 78 (2004) 2632-2636
15. Mellor A.L., and Munn D.H. Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation?. Immunol Today 20 (1999) 469-473
16. Munn D.H., Zhou M., Attwood J.T., Bondarev I., Conway S.J., Marshall B., et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281 (1998) 1191-1193
17. Mellor A.L., Sivakumar J., Chandler P., Smith K., Monila H., Mao D., et al. Prevention of T cell-driven complement activation and inflammation by tryptophan catabolism during pregnancy. Nat Immunol 2 (2001) 64-68
18. Taylor M.W., and Feng G.S. Relationship between interferon-γ, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J 5 (1991) 2516-2522
19. Alexander A.M., Crawford M., Bertera S., Rudert W.A., Takikawa O., Robbins P.D., et al. Indoleamine 2,3-dioxygenase expression in transplanted NOD islets prolongs graft survival after adoptive transfer of diabetogenic splenocytes. Diabetes 51 (2002) 356-365
20. Uyttenhove C., Pilotte L., Théate I., Stroobant V., Colau D., Parmentier N., et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 9 (2003) 1253-1254
21. Munn D.H., Sharma M.D., Hou D., Baban B., Lee J.R., Antonia S.J., et al. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest 114 (2004) 280-290
22. Yoshida R., Nukiwa T., Watanabe Y., Fujiwara M., Hirata F., and Hayaishi O. Regulation of indoleamine 2,3-dioxygenase activity in the small intestine and the epididymis of mice. Arch Biochem Biophys 203 (1980) 343-351
23. Suzuki S., Tone S., Takikawa O., Kubo T., Kohno I., and Minatogawa Y. Expression of indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase in early conception. Biochem J 355 (2001) 425-429
24. Malina H.Z., and Martin X.D. Indoleamine 2,3-dioxygenase activity in the aqueous humor, iris/ciliary body, and retina of the bovine eye. Graefe's Arch Clin Exp Ophthalmol 231 (1993) 482-486
25. Beutelspacher S.C., Pillai R., Watson M.P., Tan P.H., Tsang J., McClure M.O., et al. Function of indoleamine 2,3-dioxygenase in corneal allograft rejection and prolongation of allograft survival by over-expression. Eur J Immunol 36 3 (2006) 690-700
26. Faunce D.E., Sonoda K.H., and Stein-Streilein J. MIP-2 recruits NKT cells to the spleen during tolerance induction. J Immunol 166 (2001) 313-321
27. Cady S.G., and Sono M. 1-Methyl-dl-tryptophan, beta-(3-benzofuranyl)-dl-alanine (the oxygen analog of tryptophan), and beta-[3-benzo(b)thienyl]-dl-alanine (the sulfur analog of tryptophan) are competitive inhibitors for indoleamine 2,3-dioxygenase. Arch Biochem Biophys 291 (1991) 326-333
28. Sakurai K., Zou J.P., Tschetter J.R., Ward J.M., and Shearer G.M. Effect of indoleamine 2,3-dioxygenase on induction of experimental autoimmune encephalomyelitis. J Neuroimmunol 129 (2002) 186-196
29. Hsieh C.S., Macatonia S.E., O'Garra A., and Murphy K.M. T cell genetic background determines default T helper phenotype development in vitro. J Exp Med 181 (1995) 713-721
30. Guler M.L., Gorham J.D., Hsieh C.S., Mackey A.J., Steen R.G., Dietrich W.F., et al. Genetic susceptibility to leishmania: IL-12 responsiveness in T(h)1 cell development. Science 271 (1996) 984-987
31. Mellor A.L., Baban B., Chandler P., Marshall B., Jhaver K., Hansen A., et al. Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J Immunol 171 (2003) 1652-1655
32. + dendritic cells only after microbial stimulus. J Exp Med 196 (2002) 1307-1319
33. Martin P., Del Hoyo G.M., Anjaere F., Arias C.F., Vargas H.H., Fernandez-L A., et al. Characterization of a new subpopulation of mouse CD8α+ B220+ dendritic cells endowed with type 1 interferon production capacity and tolerogenic potential. Blood 100 (2002) 383-390
34. Munn D.H., Sharma M.D., Lee J.R., Jhaver K.G., Johnson T.S., Keskin D.B., et al. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 297 (2002) 1867-1870
35. Grohmann U., Orabona C., Fallarino F., Vacca C., Calcinaro F., Falorni A., et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 3 (2002) 1097-1101
36. + T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J Immunol 172 (2004) 4100-4110
37. Fallarino F., Grohmann U., Hwang K.W., Orabona C., Vacca C., Bianchi R., et al. Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol 4 (2003) 1206-1212
38. + T cells are required for suppressor cell production and immune privilege in the anterior chamber of the eye. Immunology 110 (2003) 18-29
39. Terness P., Bauer T.M., Röse L., Dufter C., Watzlik A., Simon H., et al. Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J Exp Med 196 (2002) 447-457
40. Frumento G., Rotondo R., Tonetti M., Damonte G., Benatti U., and Ferrara G.B. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med 196 (2002) 459-468